PL1836500T3 - Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi - Google Patents

Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi

Info

Publication number
PL1836500T3
PL1836500T3 PL06701801T PL06701801T PL1836500T3 PL 1836500 T3 PL1836500 T3 PL 1836500T3 PL 06701801 T PL06701801 T PL 06701801T PL 06701801 T PL06701801 T PL 06701801T PL 1836500 T3 PL1836500 T3 PL 1836500T3
Authority
PL
Poland
Prior art keywords
vwf
thrombocytopenia
platelets
von willebrand
willebrand factor
Prior art date
Application number
PL06701801T
Other languages
English (en)
Inventor
Groot Philip G De
Rob Fijnheer
Peter J Lenting
Karen Silence
Original Assignee
Ablynx Nv
Umc Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv, Umc Utrecht Holding Bv filed Critical Ablynx Nv
Publication of PL1836500T3 publication Critical patent/PL1836500T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/755Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/222Platelet disorders
PL06701801T 2005-01-14 2006-01-13 Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi PL1836500T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64441405P 2005-01-14 2005-01-14
PCT/EP2006/000273 WO2006074947A2 (en) 2005-01-14 2006-01-13 METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
EP06701801A EP1836500B1 (en) 2005-01-14 2006-01-13 METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS

Publications (1)

Publication Number Publication Date
PL1836500T3 true PL1836500T3 (pl) 2010-12-31

Family

ID=36593150

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06701801T PL1836500T3 (pl) 2005-01-14 2006-01-13 Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi

Country Status (13)

Country Link
US (1) US7939277B2 (pl)
EP (1) EP1836500B1 (pl)
JP (1) JP4829897B2 (pl)
AT (1) ATE473446T1 (pl)
AU (1) AU2006205900B8 (pl)
CA (1) CA2593328C (pl)
DE (1) DE602006015281D1 (pl)
DK (1) DK1836500T3 (pl)
ES (1) ES2347908T3 (pl)
PL (1) PL1836500T3 (pl)
PT (1) PT1836500E (pl)
SI (1) SI1836500T1 (pl)
WO (1) WO2006074947A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
KR20080113286A (ko) 2003-01-10 2008-12-29 아블린쓰 엔.브이. 폰 빌레브란트 인자(vWF) 또는 콜라겐에 대한 낙타과로부터의 재조합 VHH 단일 도메인 항체
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
PT1836500E (pt) 2005-01-14 2010-09-28 Ablynx Nv Métodos e ensaios para distinguir diferentes formas de doenças e perturbações caracterizadas por trombocitopenia e/ou por interacção espontânea entre o factor de von willebrand (vwf) e plaquetas
PT3415535T (pt) * 2005-05-20 2021-02-02 Ablynx Nv Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
WO2008049881A2 (en) * 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および/または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2718081A1 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
HUE027112T2 (en) * 2008-12-04 2016-08-29 Inserm (Institut Nat De La Sante Et De La Rech Medicale) Procedure for producing platelets
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
PL2473528T3 (pl) * 2009-09-03 2015-05-29 Ablynx Nv Stabilne formulacje polipeptydów i ich zastosowanie
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN106999517A (zh) 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
RU2599021C1 (ru) * 2015-07-27 2016-10-10 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ прогнозирования течения иммунной тромбоцитопении после спленэктомии по массе cd4+ т-лимфоцитов селезенки
WO2019154867A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238919A (en) 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
DE69327229T2 (de) 1992-12-11 2000-03-30 Dow Chemical Co Multivalente einkettige Antikörper
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
ATE236993T1 (de) 1994-11-30 2003-04-15 Ajinomoto Kk Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69730209T2 (de) 1996-04-04 2005-04-14 Unilever N.V. Multivalentes und multispezifisches Antigenbindungsprotein
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
US6350860B1 (en) 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DE69841562D1 (de) 1997-10-27 2010-04-29 Bac Ip Bv Multivalente antigenbindende proteine
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
CA2344606A1 (en) 1998-10-23 2000-05-04 Huabing Yuan Conformation-specific anti-von willebrand factor antibodies
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
US6419934B1 (en) 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
ES2358576T3 (es) * 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002030984A1 (en) 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20050136056A1 (en) 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
NZ563471A (en) 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
KR20080113286A (ko) 2003-01-10 2008-12-29 아블린쓰 엔.브이. 폰 빌레브란트 인자(vWF) 또는 콜라겐에 대한 낙타과로부터의 재조합 VHH 단일 도메인 항체
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
PT1836500E (pt) 2005-01-14 2010-09-28 Ablynx Nv Métodos e ensaios para distinguir diferentes formas de doenças e perturbações caracterizadas por trombocitopenia e/ou por interacção espontânea entre o factor de von willebrand (vwf) e plaquetas
PT3415535T (pt) 2005-05-20 2021-02-02 Ablynx Nv Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases

Also Published As

Publication number Publication date
EP1836500A2 (en) 2007-09-26
CA2593328A1 (en) 2006-07-20
WO2006074947A3 (en) 2006-09-14
WO2006074947A2 (en) 2006-07-20
SI1836500T1 (sl) 2010-11-30
AU2006205900B2 (en) 2011-12-08
US20080096223A1 (en) 2008-04-24
CA2593328C (en) 2018-02-06
AU2006205900A1 (en) 2006-07-20
AU2006205900B8 (en) 2012-04-05
ES2347908T3 (es) 2010-11-25
EP1836500B1 (en) 2010-07-07
DE602006015281D1 (de) 2010-08-19
ATE473446T1 (de) 2010-07-15
JP2008527358A (ja) 2008-07-24
PT1836500E (pt) 2010-09-28
US7939277B2 (en) 2011-05-10
DK1836500T3 (da) 2010-11-01
JP4829897B2 (ja) 2011-12-07
AU2006205900A8 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
SI1836500T1 (sl) Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP2315034A3 (en) Means and methods for assessing the risk of cardiac interventions based on GDF-15
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
BRPI0509419A (pt) método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
WO2008008463A3 (en) METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ
WO2005060520A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
HK1090696A1 (en) Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders
WO2006107962A8 (en) Methods and products for evaluating an immune response to a therapeutic protein
DE60228557D1 (de) Candida-nachweis
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
WO2007127936A3 (en) Methods and compositions for antibody therapy
WO2007044695A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
MXPA06012232A (es) Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.
ATE525657T1 (de) Analytisches einweg-mikroprozessorgerät
DK2054443T3 (da) Antistoffer mod en epitop fra AGR2, assays og hybridomer
ATE492815T1 (de) Diagnostik-biomolekül(e)
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2002010456A3 (en) Multiparameter analysis for predictive medicine
DK1987057T3 (da) Peptidaptamer til neutralisering af bindingen af platelet-antigen-specifikke antistoffer og diagnostiske og terapeutiske applikationer indeholdende den.
NO20082406L (no) Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen
ATE468139T1 (de) Photoreaktive verbindung mit spezifischer bindung an calciumbindende proteine
GB0706558D0 (en) Diagnostic assay
DE60122306D1 (de) Antikörper, die spezifisch für freies inaktives psa sind, und ihre verwendungen